Raytheon awarded $71 million in Navy contracts for missile systems
In a recent transaction, DSS, Inc. (NYSE:DSS), a ten percent owner of Impact Biomedical Inc. (NASDAQ:IBO), sold a significant portion of its shares in the company. The sale, which took place on April 4, 2025, involved 890,800 shares of Impact Biomedical's common stock at an average price of $0.9486 per share, totaling approximately $845,012. The transaction price represents a premium to IBO's current trading price of $0.87, with the stock showing significant volatility over the past year, trading between $0.46 and $6.17. According to InvestingPro analysis, the stock appears slightly undervalued at current levels.
Following this transaction, DSS, Inc. retains direct ownership of 161,100 shares. Additionally, the company indirectly holds 1,178,882 shares through its wholly-owned subsidiary, DSS BioHealth Security, Inc. With a market capitalization of $11.63 million and an overall Financial Health score rated as "FAIR" by InvestingPro, investors should note that IBO's current ratio of 0.25 indicates potential liquidity challenges. InvestingPro subscribers have access to 6 additional key insights about IBO's financial position.
In other recent news, Impact BioMedical Inc. has announced the acquisition of Celios®, an air purification technology company, in an all-equity deal valued at approximately $1.15 million. This strategic move aims to expand Impact BioMedical's health and wellness portfolio and boost immediate revenue streams. Celios® is recognized for its advanced air purification systems, which hold patents in the U.S. and other countries, offering exclusivity until 2043. Impact BioMedical's CEO, Frank D. Heuszel, highlighted the integration of Celios' technology as a part of the company's disciplined growth strategy.
Despite the acquisition, Impact BioMedical's stock has experienced significant fluctuations without any clear cause. The company has stated there are no new business developments that would explain the recent unusual market activity. Impact BioMedical continues its focus on developing and patenting innovative healthcare solutions. The company has reassured investors that there are no material changes in operations that could account for the stock's volatility. These developments come as Impact BioMedical maintains its mission of delivering innovative healthcare and wellness solutions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.